Omnicom’s Acxiom Names Gary Laben Chief Executive Officer

November 16, 2026
Personalized Cancer Care: When to Treat, Switch, or Stop

The next frontier of personalized cancer care: knowing when to treat, switch, or stop — Omnicom Health @ ESMO 2026

Personalized cancer care starts with choosing a treatment, but the decisions continue long after therapy begins. At ESMO 2026 in Madrid, emerging evidence raised important questions about what comes next: when to add another therapy, what should guide a switch, and whether an intervention can safely be deferred or a treatment given less often.

Five Omnicom Health colleagues share perspectives spanning esophageal cancer, immunotherapy scheduling, individualized melanoma therapy, antibody–drug conjugates, and rare tumors. Together, their insights explore how clinical evidence, prior treatment, and what patients hope to preserve or regain in daily life can shape the next step in care.

For oncology brand teams, the opportunity is to help patients and clinicians make sense of these decisions through clear education and support: who the evidence applies to, what remains uncertain, what might change the plan, and what each option would ask of the patient.

As personalized care advances, the decisions that follow treatment selection deserve the same precision as the initial choice.

Read Omnicom Health’s ESMO 2026 Insights Report

✕
✕